Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

A Rash of Evidence: Evaluating & Treating Psoriatic Arthritis

Jason Liebowitz, MD, FACR  |  November 20, 2019

ATLANTA—As many rheumatologists will recall, it was not too long ago that psoriatic arthritis was regarded somewhat like “rheumatoid arthritis with a rash,” with little attention paid to the ways in which the unique pathophysiology and manifestations of this entity make it distinct from other forms of inflammatory arthritis. At the 2019 ACR/ARP Annual Meeting…

Filed under:ConditionsPsoriatic Arthritis Tagged with:2019 ACR/ARP Annual MeetingPsoriatic Arthritis

Year in Review: Rheumatic Disease Research in 2019

Thomas R. Collins  |  November 20, 2019

ATLANTA—Encouraging data on interleukin (IL) 23/IL-17 pathway drugs in psoriatic arthritis (PsA), JAK inhibitors in rheumatoid arthritis (RA) treatment and new evidence on physical activity and bone health in women were among the highlights of the 2019 ACR/ARP Annual Meeting’s Clinical Year in Review. Susan Manzi, MD, MPH, director of the Lupus Center for Excellence…

Filed under:ConditionsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:2019 ACR/ARP Annual MeetingFracturesJAK inhibitorsKnee Osteoarthritis (OA)physical activityPsoriatic ArthritisResearch

Figures 1 & 2: Transverse and longitudinal ultrasound views, respectively, of the left posterior knee, revealing a cystic mass with heterogeneous internal echotexture and no stalk.

Ultrasound Aids Diagnosis of Man with Knee Pain & Swelling

Mark H. Greenberg, MD, RMSK, RhMSUS, Prem Patel, Elijah Mitcham, MD, James W. Fant Jr., MD, & Frank R. Voss, MD  |  November 17, 2019

A 56-year-old automobile mechanic was referred to our rheumatology service by his orthopedist to evaluate left posterior knee pain and swelling that had been present for three months. The patient had undergone bilateral total knee arthroplasties (TKAs) for sports-related osteo­arthritis three years before. In addition to the knee pain, the patient described several years of…

Filed under:ConditionsRheumatoid Arthritis Tagged with:knee arthroplastyknee swellingpopliteal cystsynovitis

Case Report: Rheumatoid Arthritis-Associated Restrictive Pericarditis

Scott Rodriguez, MD, Kenton Powell, MD, & Daniel Albert, MD  |  November 17, 2019

Rheumatoid arthritis (RA) is a systemic autoimmune disease that affects approximately 1% of the adult population, and involvement of extra-articular tissue occurs in approximately 40% of patients over their lifetimes.1 RA-associated pericardial disease is an uncommon complication, and surgery is the only definitive therapy—according to current literature. In this report, we present the case of…

Filed under:ConditionsRheumatoid Arthritis Tagged with:anti-CD20 therapyPericarditisrituximab

Scottish Medicines Consortium Recommends Risankizumab; Plus Real-World Data on Secukinumab

Michele B. Kaufman, PharmD, BCGP  |  November 4, 2019

The Scottish Medicines Consortium has released a detailed advice document recommending risankizumab for treating adults with psoriasis…

Filed under:Drug Updates Tagged with:PsoriasisrisankizumabScottish Medicines Consortiumsecukinumab

Iguratimod May Hold Promise for Treating Autoimmune Disease

Natasha Yetman  |  October 22, 2019

NEW YORK (Reuters Health)—Iguratimod, a disease-modifying drug marketed in China and Japan, appears to be effective in treating rheumatoid arthritis (RA) and possibly other autoimmune diseases, while protecting against adverse bone effects, researchers from China say. Iguratimod is a methane sulfonanilide compound that influences several anti-inflammatory and immune-modulatory pathways and has an anabolic effect on…

Filed under:Drug Updates Tagged with:Autoimmune diseaseboneChinaiguratimod

Insights into Interstitial Lung Disease in Rheumatoid Arthritis Patients

Jason Liebowitz, MD, FACR  |  October 18, 2019

MADRID—Rheumatoid arthritis (RA) is among the most common autoimmune diseases in the U.S., affecting approximately 1.3 million U.S. adults.1 Although tremendous treatment advances have been made in recent years, one extra-articular manifestation of RA that continues to pose a challenge with regard to detection and management is interstitial lung disease (ILD). At the 2019 European…

Filed under:ConditionsRheumatoid Arthritis Tagged with:EULARInterstitial Lung Disease

Researchers Seek the Best Methods to Maintain Remission in Vasculitis

Jason Liebowitz, MD, FACR  |  October 18, 2019

MADRID—During the 2019 European Congress of Rheumatology (EULAR), held June 12–15, speakers addressed the complexity of vasculitis in a Challenges in Clinical Practice session titled, How to Maintain Remission in Vasculitis. Although vasculitis appears in many varieties, one commonality exists among these related yet distinct conditions: When there is vital organ or systemic involvement, disease…

Filed under:ConditionsResearch RheumVasculitis Tagged with:EULARRemission

Case Report: A Patient Develops Scleroderma Renal Crisis

Adria Madera-Acosta, MD, Teresa Sosenko, MD, & Diana Girnita, MD, PhD  |  October 18, 2019

Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis. SRC occurs in 2–15% of patients with diffuse sclerosis and usually within the first five years from the time of diagnosis. Risk factors for SRC include, but are not limited to, early diagnosis, corticosteroid or cyclosporine use, and the presence of anti-RNA polymerase III…

Filed under:ConditionsSystemic Sclerosis Tagged with:case reportdiffuse systemic sclerosisScleroderma Renal Crisis

Case Report: A Patient on Apremilast Develops Streptococcus Salivarius

Stephanie Kydd Dondero, DO, & Barry Waters, MD  |  October 18, 2019

Apremilast was first marketed in March 2014 for the treatment of adults with psoriatic arthritis (PsA). An immuno­modulating drug, which is a small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine mono­phosphate (cAMP), apremilast is administered orally. By inhibiting PDE4, intracellular cAMP levels are increased. Although the exact mechanism of action is not…

Filed under:Conditions Tagged with:apremilastcase reportimmunosuppressive drugsStreptococcus salivarius

  • « Previous Page
  • 1
  • …
  • 37
  • 38
  • 39
  • 40
  • 41
  • …
  • 105
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences